IRIS
BARCHIESI, Francesco
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 9.584
EU - Europa 4.751
AS - Asia 4.486
SA - Sud America 1.219
AF - Africa 243
Continente sconosciuto - Info sul continente non disponibili 7
OC - Oceania 4
Totale 20.294
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 9.423
SG - Singapore 1.382
VN - Vietnam 1.005
BR - Brasile 924
RU - Federazione Russa 797
UA - Ucraina 788
IT - Italia 691
CN - Cina 578
DE - Germania 466
IE - Irlanda 461
TR - Turchia 457
SE - Svezia 382
HK - Hong Kong 347
FR - Francia 292
DK - Danimarca 283
FI - Finlandia 213
GB - Regno Unito 197
KR - Corea 158
AR - Argentina 109
IN - India 100
BD - Bangladesh 98
CI - Costa d'Avorio 95
CA - Canada 65
MX - Messico 64
EC - Ecuador 49
ZA - Sudafrica 49
ID - Indonesia 48
NL - Olanda 44
IQ - Iraq 42
CO - Colombia 36
JP - Giappone 30
PL - Polonia 28
PK - Pakistan 27
PY - Paraguay 26
CL - Cile 25
MA - Marocco 25
IR - Iran 24
AT - Austria 22
PH - Filippine 22
VE - Venezuela 21
UZ - Uzbekistan 20
ES - Italia 17
MY - Malesia 16
SA - Arabia Saudita 16
BE - Belgio 15
AZ - Azerbaigian 13
EG - Egitto 13
TN - Tunisia 13
PE - Perù 12
KZ - Kazakistan 11
UY - Uruguay 11
KE - Kenya 10
NP - Nepal 10
JO - Giordania 9
TH - Thailandia 9
BA - Bosnia-Erzegovina 8
DZ - Algeria 8
IL - Israele 7
KW - Kuwait 7
CR - Costa Rica 6
ET - Etiopia 6
EU - Europa 6
LB - Libano 6
AE - Emirati Arabi Uniti 5
AL - Albania 5
CZ - Repubblica Ceca 5
DO - Repubblica Dominicana 5
HN - Honduras 5
JM - Giamaica 5
LT - Lituania 5
MD - Moldavia 5
PS - Palestinian Territory 5
AO - Angola 4
AU - Australia 4
BH - Bahrain 4
BO - Bolivia 4
BY - Bielorussia 4
KG - Kirghizistan 4
NG - Nigeria 4
PA - Panama 4
SY - Repubblica araba siriana 4
TW - Taiwan 4
AM - Armenia 3
CM - Camerun 3
HR - Croazia 3
LK - Sri Lanka 3
NO - Norvegia 3
OM - Oman 3
PT - Portogallo 3
SN - Senegal 3
TT - Trinidad e Tobago 3
BG - Bulgaria 2
CH - Svizzera 2
GE - Georgia 2
GY - Guiana 2
MU - Mauritius 2
QA - Qatar 2
RO - Romania 2
RS - Serbia 2
A1 - Anonimo 1
Totale 20.271
Salva come PNG Salva come JPEG
Città #
Ashburn 1.561
Singapore 845
Jacksonville 794
Fairfield 742
Dallas 636
Chandler 537
Dublin 455
Boardman 422
Hong Kong 324
Ho Chi Minh City 323
Wilmington 316
Woodbridge 304
San Jose 294
Seattle 256
New York 255
Houston 252
Des Moines 243
Cambridge 241
Hanoi 224
The Dalles 201
Ann Arbor 193
Lawrence 173
Princeton 173
San Mateo 172
Lauterbourg 151
Moscow 142
Los Angeles 126
Beijing 118
Turin 107
San Diego 98
Abidjan 95
Hefei 88
Munich 87
Milan 85
São Paulo 76
Council Bluffs 67
Da Nang 64
Buffalo 54
Centro 51
Chicago 45
Haiphong 44
Redmond 41
Helsinki 40
London 40
Rio de Janeiro 32
Nuremberg 31
Santa Clara 28
Ancona 27
Brooklyn 27
Miano 27
Shanghai 26
Turku 26
Tokyo 24
Columbus 23
Frankfurt am Main 22
Johannesburg 22
Orem 22
Biên Hòa 21
Montreal 21
Warsaw 20
Tashkent 19
Guangzhou 18
Mexico City 18
Norwalk 18
Washington 18
Baghdad 17
Chennai 17
Dhaka 17
Guayaquil 17
Belo Horizonte 16
Marche 16
Ninh Bình 16
Ottawa 16
Pune 16
Boston 15
Brasília 15
Nha Trang 15
Quito 15
Amsterdam 14
Brussels 14
Curitiba 14
Porto Alegre 14
Salt Lake City 14
Wuhan 14
Ankara 13
Atlanta 13
Hải Dương 13
Kilburn 13
Rome 13
Stockholm 13
Cape Town 12
Asunción 11
Baku 11
Bologna 11
Denver 11
Manchester 11
Mumbai 11
Poplar 11
Campinas 10
Caracas 10
Totale 12.524
Salva come PNG Salva come JPEG
Nome #
Antimicrobial Resistance: A Challenge for the Future 303
Activity of nitazoxanide alone and in combination with azithromycin and rifabutin against Cryptosporidium parvum in cell culture. 207
An (Italian) proposal for a comprehensive approach to infections across the surgical pathway 199
Carbapenem-Resistant Klebsiella pneumoniae influences the outcome of early infections in liver transplant recipients 196
Activity of buforin II alone and in combination with azithromycin and minocycline against Cryptosporidium parvum in cell culture. 189
ACTIVITY OF THE NEW ANTIFUNGAL TRIAZOLE, POSACONAZOLE, AGAINST CRYPTOCOCCUS NEOFORMANS 188
Candida guilliermondii fungemia in patients with hematologic malignancies. 186
Aspergillus spp invasive external otitis: favourable outcome with a medical approach 185
Bloodstream infections in the COVID-19 era: results from an Italian multi-centre study 185
Antimicrobial activity of polycationic peptides 182
Invasive Aspergillosis in liver transplant recipients: Epidemiology, clinical characteristics, treatment, and outcomes in 116 cases 181
Ceftazidime-Avibactam for the Treatment of Multidrug-Resistant Pathogens: A Retrospective, Single Center Study 174
Epidemiology and outcome of systemic infections due to saprochaete capitata: case report and review of the literature 171
Candidemia in intensive care units over nine years at a large Italian university hospital: Comparison with other wards 165
Delay of antifungal therapy influences the outcome of invasive aspergillosis in experimental models of infection 162
Acute histoplasmosis in immunocompetent travelers: a systematic review of literature 161
Anidulafungin in combination with amphotericin B against Aspergillus fumigatus. 160
Epidemiology, clinical characteristics, and outcome of candidemia in a tertiary referral center in Italy from 2010 to 2014 157
Candidemia in the elderly: What does it change? 153
Epidemiology and microbiology of surgical wound infections. 152
Prevalence and predictors of malignancies in a polycentric cohort of HIV patients from Italy 152
Effects of caspofungin against Candida guilliermondii and Candida parapsilosis. 152
Characterisation of candidemia in patients with recent surgery: A 7-year experience 151
Atazanavir/ritonavir with lamivudine as maintenance therapy in virologically suppressed HIV-infected patients: 96 week outcomes of a randomized trial 150
Species distribution and antifungal susceptibilities of bloodstream Candida isolates: a nine-years single center survey 148
Multicentre validation of a EUCAST method for the antifungal susceptibility testing of microconidia-forming dermatophytes 147
Analysis of antibody response to Cryptococcus neoformans in five patients with AIDS and cryptococcosis by immunoblotting. 146
Anticryptosporidial activity of ranalexin, lasalocid and azithromycin alone and in combination in cell lines. 146
In-vitro effect of short-term exposure to two synthetic peptides, alone or in combination with clarithromycin or rifabutin, on Cryptosporidium parvum infectivity. 144
Comparison of liver fibrosis progression in HIV/HCV co-infected and HCV mono-infected patients by transient elastometry 143
Factors related to outcome of bloodstream infections due to Candida parapsilosis complex 141
Effectiveness of remdesivir in patients with COVID-19 under mechanical ventilation in an Italian ICU 141
Evaluating Liver Fibrosis by Transient Elastometry in Patients With HIV-HCV Coinfection and Monoinfection. 138
In-vitro activity of the synthetic protegrin IB-367 alone and in combination with antifungal agents against clinical isolates of Candida spp. 136
Changing characteristics and risk factors of patients with and without incident HCV infection among HIV-infected individuals 136
Trichosporon beigelii fungaemia in an AIDS patient. 136
High rate of ceftobiprole resistance among clinical methicillin-resistant Staphylococcus aureus isolates from a hospital in central Italy 136
Genotypic and phenotypic characteristics of Candida parapsilosis bloodstream isolates: Health Care Associated Infections in a teaching Hospital in Italy 135
Candidemia in Internal Medicine: Facing the New Challenge 134
Antifungal Combinations against Candida Species: From Bench to Bedside 133
Comparison of three methods for testing azole susceptibilities of Candida albicans strains isolated sequentially from the oral cavities of aids patients. 131
Clinical and epidemiological characteristics of KPC-producing Klebsiella pneumoniae from bloodstream infections in a tertiary referral center in Italy 131
Antifungal combinations in dermatophytes 131
Statistical analyses of correlation between fluconazole MICs for Candida spp. assessed by standard methods set forth by the European Committee on Antimicrobial Susceptibility Testing (E.Dis. 7.1) and CLSI (M27-A2). 130
Heterozygosis and pathogenicity of Cryptococcus neoformans AD-hybrid isolates. 130
Osteomyelitis caused by Aspergillusspecies: a review of 310 reported cases 130
Anticryptosporidial activity of cationic peptides alone and in combination with inhibitors of ion transport systems. 130
Clinical efficacy and tolerability of caspofungin in a renal transplant patient with Aspergillus flavus lung infection: case report. 127
Comparison of visual 24-hour and spectrophotometric 48-hour MICs to CLSI reference microdilution MICs of fluconazole, itraconazole, posaconazole, and voriconazole for Candida spp.: a collaborative study. 125
A comparative analysis of unintegrated HIV-1 DNA measurement as a potential biomarker of the cellular reservoir in the blood of patients controlling and non-controlling viral replication 125
Sequential therapy with caspofungin and fluconazole for Candida albicans infection. 124
Antifungal susceptibility patterns of yeast isolates causing bloodstream infections. 124
Development and validation of a prediction model for severe respiratory failure in hospitalized patients with SARS-CoV-2 infection: a multicentre cohort study (PREDI-CO study) 123
Experimental induction of fluconazole resistance in Candida tropicalis ATCC 750. 122
EUCAST technical note on posaconazole. 122
Antiretroviral therapy management and rationalisation of available resources 122
Posaconazole against Candida glabrata isolates with various susceptibilities to fluconazole. 121
Effects of amphotericin B on Aspergillus flavus clinical isolates with variable susceptibilities to the polyene in an experimental model of systemic aspergillosis. 121
Central venous catheter unrelated candidemia influences the outcome of infection in patients with solid tumors 120
Epidemiology of candidaemia and antifungal susceptibility patterns in an Italian tertiary-care hospital. 119
Interactions of posaconazole and flucytosine against Cryptococcus neoformans. 118
In vitro activity of the protegrin IB-367 alone and in combination compared with conventional antifungal agents against dermatophytes 115
In-vitro activity of rifabutin and albendazolo singly and in combination with other clinically used antimicrobial agents against Pneumocystis carinii. 114
Comparison between disk diffusion and microdilution methods for determining susceptibility of clinical fungal isolates to caspofungin. 114
Evaluation of the disk diffusion method compared to the microdilution method in susceptibility testing of anidulafungin against filamentous fungi. 113
In vitro activities of membrane-active peptides alone and in combination with clinically used antimicrobial agents against Stenotrophomonas maltophilia. 113
Turbidimetric and visual criteria for determining the in vitro activity of six antifungal agents against Candida spp. and Cryptococcus neoformans. 112
Reply to Ma et al.: Osteomyelitis caused by aspergillus species 112
In vitro activity of the lipopeptide derivative (Pal-Lys-Lys-NH), alone and in combination with antifungal agents, against clinical isolates of dermatophytes. 111
Comparative Effects of Micafungin, Caspofungin, and Anidulafungin against a Difficult-To-Treat Fungal Opportunistic Pathogen, Candida glabrata 111
Voriconazole and multidrug resistance in Candida albicans. 111
EUCAST Technical Note on voriconazole. 111
Comparison of the fungicidal activities of caspofungin and amphotericin B against Candida glabrata. 111
In-vitro activity of five antifungal agents against uncommon clinical isolates of Candida spp. 110
In-vitro activity of polycationic peptides against Cryptosporidium parvum, Pneumocystis carinii and yeast clinical isolates. 110
Infection due to Absidia corymbifera in a patient with a massive crush trauma of the foot 110
Prevalence and predictors of malignancies in HIV patients: results of a retrospective multicentric Italian cohort. 110
In vitro activities of voriconazole in combination with other three antifungal agents against Candida glabrata 109
EUCAST definitive document EDef 7.1: method for the determination of broth dilution MICs of antifungal agents for fermentative yeasts. 109
In vitro activities of terbinafine in combination with fluconazole and itraconazole against isolates of Candida albicans with reduced susceptibility to azoles. 109
Candidemia: Evolution of Drug Resistance and Novel Therapeutic Approaches 109
Tolerance to amphotericin B in clinical isolates of Candida tropicalis. 108
How to: EUCAST recommendations on the screening procedure E.Def 10.1 for the detection of azole resistance in Aspergillus fumigatus isolates using four-well azole-containing agar plates 108
Interactions of Posaconazole and Flucytosine against Cryptococcus neoformans. Antimicrob. Agents Chemother. 107
Caspofungin in combination with amphotericin B against Candida parapsilosis. 106
Posaconazole activity against Candida glabrata after exposure to caspofungin or amphotericin B. 106
International and multicenter comparison of EUCAST and CLSI M27-A2 broth microdilution methods for testing susceptibilities of Candida spp. to fluconazole, itraconazole, posaconazole, and voriconazole. 106
Molecular epidemiology of Italian clinical Cryptococcus neoformans var. grubii isolates 106
Comparison of four methods for DNA typing of clinical isolates of Candida glabrata. 105
In vitro activity of Tachyplesin III alone and in combination with terbinafine against clinical isolates of dermatophytes. 105
EUCAST technical note on Amphotericin B 105
In vitro susceptibility of dermatophytes to conventional and alternative antifungal agents. 105
Sustained increase of serum creatine phosphokinase levels and progressive muscle abnormalities associated with raltegravir use during 32-week follow-up in an HIV-1 experienced patient on simplified HAART regimen, intolerant to protease inhibitors and abacavir: a case report. 105
The Clinical Characteristics of Bloodstream Infections Due to Candida spp. in Patients Hospitalized in Intensive Care Units during the SARS-CoV-2 Pandemic: The Results of a Multicenter Study 104
Epidemiology of onychomycosis and paronychia in the area of ANCONA (ITALY) over a period of 5 years 104
Electrophoretic karyotyping and antifungal susceptibility patterns of Candida parapsilosis clinical isolates causing deep and superficial fungal infections 104
In vitro and in vivo effects of echinocandins against Candida parapsilosis sensu stricto, Candida orthopsilosis and Candida metapsilosis. 103
Caspofungin in combination with amphotericin B against Candida glabrata. 103
In-vitro interaction of terbinafine with amphotericin B, fluconazole and itraconazole against clinical isolates of Candida albicans. 102
In vitro activities of voriconazole in combination with three other antifungal agents against Candida glabrata. 102
Totale 13.345
Salva come PNG Salva come JPEG
Categoria #
all - tutte 95.791
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 95.791
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021108 0 0 0 0 0 0 0 0 0 0 0 108
2021/20221.519 133 433 13 42 20 63 117 70 76 136 156 260
2022/20232.071 215 172 150 113 135 354 13 96 563 11 176 73
2023/20241.297 214 25 68 240 248 280 26 18 15 14 15 134
2024/20252.350 212 203 166 29 61 60 168 112 609 161 238 331
2025/20268.193 414 589 765 1.144 668 404 1.388 762 708 699 307 345
Totale 20.529